Letters
Living WHO guideline on molnupiravir for covid-19
Molnupiravir might be dangerous without clarification of its indications
BMJ 2022; 377 doi: https://doi.org/10.1136/bmj.o1030 (Published 26 April 2022) Cite this as: BMJ 2022;377:o1030
- Keiji Hayashi, medical doctor
- Hayashi Children’s Clinic, Osaka, Japan
- hayashi{at}kch.biglobe.ne.jp
The data on which the approval of molnupiravir was based in Japan1 and the data reported by Bernal et al2 are worrying and emphasise the huge unknowns around the use of molnupiravir.3
The first problem is efficacy estimates that change substantially over time. In the interim analysis, the relative risk (RR) for hospital admission for any cause or death through day 29 was 0.52 (95% confidence interval 0.34 …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.